PTHrP and breast cancer: more than hypercalcemia and bone metastases
- PMID: 22546075
- PMCID: PMC3446368
- DOI: 10.1186/bcr3129
PTHrP and breast cancer: more than hypercalcemia and bone metastases
Abstract
Parathyroid hormone-related protein (PTHrP) causes hypercalcemia in cancer patients. PTHrP is required for normal breast development and has been shown to promote bone metastases from breast cancers. However, whether the protein also contributes to the formation of primary tumors has been unclear. Two recent papers suggest it may. First, a report in Nature Genetics identified the PTHrP locus as a new breast cancer susceptibility gene. Second, a paper in Journal of Clinical Investigation demonstrated that PTHrP promotes tumor growth and metastases in MMTV-PyMT mice. These studies implicate PTHrP in the development and growth of primary breast tumors and underscore the need for further research.
Comment on
-
PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target.J Clin Invest. 2011 Dec;121(12):4655-69. doi: 10.1172/JCI46134. Epub 2011 Nov 7. J Clin Invest. 2011. PMID: 22056386 Free PMC article.
-
Genome-wide association analysis identifies three new breast cancer susceptibility loci.Nat Genet. 2012 Jan 22;44(3):312-8. doi: 10.1038/ng.1049. Nat Genet. 2012. PMID: 22267197 Free PMC article.
References
-
- Wysolmerski J. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 7. Rosen C, editor. Washington, DC: American Society for Bone and Mineral Research; 2008. Parathyroid hormone-related protein; pp. 127–133.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
